IACH Focus on Leukemia 2020 | The 2020 highlights in MDS
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discusses the drugs in development for myelodysplastic syndromes (MDS). For lower-risk MDS, Prof. Cluzeau highlights the Phase III trial of luspatercep in patients with lower-risk MDS with ring sideroblasts as well as the Phase II trial results of imetelstat, a telomerase inhibitor, that shows good transfusion independence. Prof. Cluzeau also discusses the Phase I results of roxadustat, an oral HIF prolyl-hydroxylase inhibitor currently being evaluated in lower-risk MDS with anemia. For the treatment of higher-risk MDS, Prof. Cluzeau outlines novel agents under investigation, including APR-246 in combination with azacitidine as well as magrolimab, a CD47 inhibitor and pevonedistat, a selective NEDD8 inhibitor. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).
Disclosures
Clinical Research: Aprea (PI GFM APR), Novartis, Alexion, Celgene/BMS, Amgen, Syros, Kartos, Arog
Advisory boards: Celgene, Abbvie, Jazz Pharma, Roche, Novartis, Agios
Education: Novartis, Amgen, Sanofi, Astellas
International congresses: Sanofi, Pfizer, Celgene, Novartis
